JP2012508016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508016A5 JP2012508016A5 JP2011535649A JP2011535649A JP2012508016A5 JP 2012508016 A5 JP2012508016 A5 JP 2012508016A5 JP 2011535649 A JP2011535649 A JP 2011535649A JP 2011535649 A JP2011535649 A JP 2011535649A JP 2012508016 A5 JP2012508016 A5 JP 2012508016A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- germline
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004602 germ cell Anatomy 0.000 claims 73
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 39
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 39
- 239000000427 antigen Substances 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 230000027455 binding Effects 0.000 claims 37
- 108090000623 proteins and genes Proteins 0.000 claims 25
- -1 MMP inhibitor Proteins 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 5
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 239000000816 peptidomimetic Substances 0.000 claims 5
- 230000005714 functional activity Effects 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 claims 2
- 101001079285 Homo sapiens Immunoglobulin heavy joining 1 Proteins 0.000 claims 2
- 101001091242 Homo sapiens Immunoglobulin kappa joining 1 Proteins 0.000 claims 2
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 claims 2
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 claims 2
- 101001047629 Homo sapiens Immunoglobulin kappa variable 2-30 Proteins 0.000 claims 2
- 101001134437 Homo sapiens Immunoglobulin lambda joining 1 Proteins 0.000 claims 2
- 101000978126 Homo sapiens Immunoglobulin lambda variable 8-61 Proteins 0.000 claims 2
- 102100028078 Immunoglobulin heavy joining 1 Human genes 0.000 claims 2
- 102100034892 Immunoglobulin kappa joining 1 Human genes 0.000 claims 2
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 claims 2
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 claims 2
- 102100022952 Immunoglobulin kappa variable 2-30 Human genes 0.000 claims 2
- 102100034172 Immunoglobulin lambda joining 1 Human genes 0.000 claims 2
- 102100023752 Immunoglobulin lambda variable 8-61 Human genes 0.000 claims 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100040843 C-type lectin domain family 4 member M Human genes 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
- 102100036509 Erythropoietin receptor Human genes 0.000 claims 1
- 101710102442 Erythropoietin receptor Proteins 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- 108010008177 Fd immunoglobulins Proteins 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims 1
- 101710142125 Granulocyte colony-stimulating factor receptor Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000749311 Homo sapiens C-type lectin domain family 4 member M Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101000843762 Homo sapiens Immunoglobulin heavy diversity 1-1 Proteins 0.000 claims 1
- 101000998950 Homo sapiens Immunoglobulin heavy variable 1-18 Proteins 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101000998949 Homo sapiens Immunoglobulin heavy variable 1-24 Proteins 0.000 claims 1
- 101000998952 Homo sapiens Immunoglobulin heavy variable 1-3 Proteins 0.000 claims 1
- 101000998948 Homo sapiens Immunoglobulin heavy variable 1-45 Proteins 0.000 claims 1
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 claims 1
- 101001002931 Homo sapiens Immunoglobulin heavy variable 1-58 Proteins 0.000 claims 1
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 claims 1
- 101000998951 Homo sapiens Immunoglobulin heavy variable 1-8 Proteins 0.000 claims 1
- 101001037152 Homo sapiens Immunoglobulin heavy variable 2-26 Proteins 0.000 claims 1
- 101001037145 Homo sapiens Immunoglobulin heavy variable 2-5 Proteins 0.000 claims 1
- 101001037151 Homo sapiens Immunoglobulin heavy variable 2-70 Proteins 0.000 claims 1
- 101001037138 Homo sapiens Immunoglobulin heavy variable 3-11 Proteins 0.000 claims 1
- 101001037137 Homo sapiens Immunoglobulin heavy variable 3-13 Proteins 0.000 claims 1
- 101001037136 Homo sapiens Immunoglobulin heavy variable 3-15 Proteins 0.000 claims 1
- 101001037142 Homo sapiens Immunoglobulin heavy variable 3-20 Proteins 0.000 claims 1
- 101001037141 Homo sapiens Immunoglobulin heavy variable 3-21 Proteins 0.000 claims 1
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 claims 1
- 101001037139 Homo sapiens Immunoglobulin heavy variable 3-30 Proteins 0.000 claims 1
- 101001037143 Homo sapiens Immunoglobulin heavy variable 3-33 Proteins 0.000 claims 1
- 101000839665 Homo sapiens Immunoglobulin heavy variable 3-43 Proteins 0.000 claims 1
- 101000839662 Homo sapiens Immunoglobulin heavy variable 3-48 Proteins 0.000 claims 1
- 101000839663 Homo sapiens Immunoglobulin heavy variable 3-49 Proteins 0.000 claims 1
- 101000839660 Homo sapiens Immunoglobulin heavy variable 3-53 Proteins 0.000 claims 1
- 101000839661 Homo sapiens Immunoglobulin heavy variable 3-64 Proteins 0.000 claims 1
- 101000839658 Homo sapiens Immunoglobulin heavy variable 3-66 Proteins 0.000 claims 1
- 101001037153 Homo sapiens Immunoglobulin heavy variable 3-7 Proteins 0.000 claims 1
- 101000839659 Homo sapiens Immunoglobulin heavy variable 3-72 Proteins 0.000 claims 1
- 101000839657 Homo sapiens Immunoglobulin heavy variable 3-73 Proteins 0.000 claims 1
- 101000839687 Homo sapiens Immunoglobulin heavy variable 3-74 Proteins 0.000 claims 1
- 101001037144 Homo sapiens Immunoglobulin heavy variable 3-9 Proteins 0.000 claims 1
- 101000839683 Homo sapiens Immunoglobulin heavy variable 4-28 Proteins 0.000 claims 1
- 101000839684 Homo sapiens Immunoglobulin heavy variable 4-31 Proteins 0.000 claims 1
- 101000839682 Homo sapiens Immunoglobulin heavy variable 4-34 Proteins 0.000 claims 1
- 101000839679 Homo sapiens Immunoglobulin heavy variable 4-39 Proteins 0.000 claims 1
- 101000839686 Homo sapiens Immunoglobulin heavy variable 4-4 Proteins 0.000 claims 1
- 101000839781 Homo sapiens Immunoglobulin heavy variable 4-59 Proteins 0.000 claims 1
- 101000989076 Homo sapiens Immunoglobulin heavy variable 4-61 Proteins 0.000 claims 1
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 claims 1
- 101000989060 Homo sapiens Immunoglobulin heavy variable 6-1 Proteins 0.000 claims 1
- 101001138126 Homo sapiens Immunoglobulin kappa variable 1-16 Proteins 0.000 claims 1
- 101001138125 Homo sapiens Immunoglobulin kappa variable 1-17 Proteins 0.000 claims 1
- 101001138123 Homo sapiens Immunoglobulin kappa variable 1-27 Proteins 0.000 claims 1
- 101001138121 Homo sapiens Immunoglobulin kappa variable 1-33 Proteins 0.000 claims 1
- 101001138133 Homo sapiens Immunoglobulin kappa variable 1-5 Proteins 0.000 claims 1
- 101001138132 Homo sapiens Immunoglobulin kappa variable 1-6 Proteins 0.000 claims 1
- 101001138131 Homo sapiens Immunoglobulin kappa variable 1-8 Proteins 0.000 claims 1
- 101001138130 Homo sapiens Immunoglobulin kappa variable 1-9 Proteins 0.000 claims 1
- 101001008259 Homo sapiens Immunoglobulin kappa variable 1D-12 Proteins 0.000 claims 1
- 101001008261 Homo sapiens Immunoglobulin kappa variable 1D-13 Proteins 0.000 claims 1
- 101001008333 Homo sapiens Immunoglobulin kappa variable 1D-16 Proteins 0.000 claims 1
- 101001008329 Homo sapiens Immunoglobulin kappa variable 1D-33 Proteins 0.000 claims 1
- 101001008313 Homo sapiens Immunoglobulin kappa variable 1D-39 Proteins 0.000 claims 1
- 101001009877 Homo sapiens Immunoglobulin kappa variable 1D-43 Proteins 0.000 claims 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047626 Homo sapiens Immunoglobulin kappa variable 2-24 Proteins 0.000 claims 1
- 101001047627 Homo sapiens Immunoglobulin kappa variable 2-28 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001047625 Homo sapiens Immunoglobulin kappa variable 2-40 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001008323 Homo sapiens Immunoglobulin kappa variable 2D-28 Proteins 0.000 claims 1
- 101001008325 Homo sapiens Immunoglobulin kappa variable 2D-29 Proteins 0.000 claims 1
- 101001008293 Homo sapiens Immunoglobulin kappa variable 2D-40 Proteins 0.000 claims 1
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 claims 1
- 101001047618 Homo sapiens Immunoglobulin kappa variable 3-15 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008257 Homo sapiens Immunoglobulin kappa variable 3D-11 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 101001008315 Homo sapiens Immunoglobulin kappa variable 3D-20 Proteins 0.000 claims 1
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 claims 1
- 101000605181 Homo sapiens Immunoglobulin kappa variable 5-2 Proteins 0.000 claims 1
- 101001090250 Homo sapiens Immunoglobulin kappa variable 6-21 Proteins 0.000 claims 1
- 101001008317 Homo sapiens Immunoglobulin kappa variable 6D-21 Proteins 0.000 claims 1
- 101001054844 Homo sapiens Immunoglobulin lambda variable 1-36 Proteins 0.000 claims 1
- 101001054843 Homo sapiens Immunoglobulin lambda variable 1-40 Proteins 0.000 claims 1
- 101001054838 Homo sapiens Immunoglobulin lambda variable 1-44 Proteins 0.000 claims 1
- 101001054837 Homo sapiens Immunoglobulin lambda variable 1-47 Proteins 0.000 claims 1
- 101001054839 Homo sapiens Immunoglobulin lambda variable 1-51 Proteins 0.000 claims 1
- 101000578462 Homo sapiens Immunoglobulin lambda variable 10-54 Proteins 0.000 claims 1
- 101000956884 Homo sapiens Immunoglobulin lambda variable 2-11 Proteins 0.000 claims 1
- 101000956885 Homo sapiens Immunoglobulin lambda variable 2-14 Proteins 0.000 claims 1
- 101000956888 Homo sapiens Immunoglobulin lambda variable 2-18 Proteins 0.000 claims 1
- 101000956889 Homo sapiens Immunoglobulin lambda variable 2-23 Proteins 0.000 claims 1
- 101000956887 Homo sapiens Immunoglobulin lambda variable 2-8 Proteins 0.000 claims 1
- 101001005360 Homo sapiens Immunoglobulin lambda variable 3-1 Proteins 0.000 claims 1
- 101001005361 Homo sapiens Immunoglobulin lambda variable 3-10 Proteins 0.000 claims 1
- 101001005362 Homo sapiens Immunoglobulin lambda variable 3-12 Proteins 0.000 claims 1
- 101001005363 Homo sapiens Immunoglobulin lambda variable 3-16 Proteins 0.000 claims 1
- 101001005364 Homo sapiens Immunoglobulin lambda variable 3-19 Proteins 0.000 claims 1
- 101001005365 Homo sapiens Immunoglobulin lambda variable 3-21 Proteins 0.000 claims 1
- 101001005366 Homo sapiens Immunoglobulin lambda variable 3-22 Proteins 0.000 claims 1
- 101001005336 Homo sapiens Immunoglobulin lambda variable 3-25 Proteins 0.000 claims 1
- 101001005337 Homo sapiens Immunoglobulin lambda variable 3-27 Proteins 0.000 claims 1
- 101001005329 Homo sapiens Immunoglobulin lambda variable 3-9 Proteins 0.000 claims 1
- 101001005330 Homo sapiens Immunoglobulin lambda variable 4-3 Proteins 0.000 claims 1
- 101001005331 Homo sapiens Immunoglobulin lambda variable 4-60 Proteins 0.000 claims 1
- 101001005332 Homo sapiens Immunoglobulin lambda variable 4-69 Proteins 0.000 claims 1
- 101001005333 Homo sapiens Immunoglobulin lambda variable 5-37 Proteins 0.000 claims 1
- 101001005334 Homo sapiens Immunoglobulin lambda variable 5-39 Proteins 0.000 claims 1
- 101001005335 Homo sapiens Immunoglobulin lambda variable 5-45 Proteins 0.000 claims 1
- 101000978130 Homo sapiens Immunoglobulin lambda variable 5-52 Proteins 0.000 claims 1
- 101000978133 Homo sapiens Immunoglobulin lambda variable 6-57 Proteins 0.000 claims 1
- 101000978132 Homo sapiens Immunoglobulin lambda variable 7-43 Proteins 0.000 claims 1
- 101000978127 Homo sapiens Immunoglobulin lambda variable 7-46 Proteins 0.000 claims 1
- 101000978129 Homo sapiens Immunoglobulin lambda variable 9-49 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims 1
- 101001037135 Homo sapiens Probable non-functional immunoglobulin heavy variable 3-16 Proteins 0.000 claims 1
- 101001037134 Homo sapiens Probable non-functional immunoglobulin heavy variable 3-35 Proteins 0.000 claims 1
- 101000839664 Homo sapiens Probable non-functional immunoglobulin heavy variable 3-38 Proteins 0.000 claims 1
- 101000989063 Homo sapiens Probable non-functional immunoglobulin heavy variable 7-81 Proteins 0.000 claims 1
- 101001009876 Homo sapiens Probable non-functional immunoglobulin kappa variable 1D-42 Proteins 0.000 claims 1
- 101001008319 Homo sapiens Probable non-functional immunoglobulin kappa variable 2D-24 Proteins 0.000 claims 1
- 101001047520 Homo sapiens Probable non-functional immunoglobulin kappa variable 3-7 Proteins 0.000 claims 1
- 101001009875 Homo sapiens Probable non-functional immunoglobulin kappa variable 6D-41 Proteins 0.000 claims 1
- 101001054840 Homo sapiens Probable non-functional immunoglobulin lambda variable 1-50 Proteins 0.000 claims 1
- 101000978120 Homo sapiens Probable non-functional immunoglobulin lambda variable 11-55 Proteins 0.000 claims 1
- 101000956613 Homo sapiens Probable non-functional immunoglobulin lambda variable 2-33 Proteins 0.000 claims 1
- 101001005338 Homo sapiens Probable non-functional immunoglobulin lambda variable 3-32 Proteins 0.000 claims 1
- 101001138120 Homo sapiens Probable non-functional immunoglobulinn kappa variable 1-37 Proteins 0.000 claims 1
- 101001008331 Homo sapiens Probable non-functional immunoglobulinn kappa variable 1D-37 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 102100030644 Immunoglobulin heavy diversity 1-1 Human genes 0.000 claims 1
- 102100036884 Immunoglobulin heavy variable 1-18 Human genes 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100036890 Immunoglobulin heavy variable 1-24 Human genes 0.000 claims 1
- 102100036886 Immunoglobulin heavy variable 1-3 Human genes 0.000 claims 1
- 102100036889 Immunoglobulin heavy variable 1-45 Human genes 0.000 claims 1
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 claims 1
- 102100020774 Immunoglobulin heavy variable 1-58 Human genes 0.000 claims 1
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 claims 1
- 102100036885 Immunoglobulin heavy variable 1-8 Human genes 0.000 claims 1
- 102100040230 Immunoglobulin heavy variable 2-26 Human genes 0.000 claims 1
- 102100040235 Immunoglobulin heavy variable 2-5 Human genes 0.000 claims 1
- 102100040233 Immunoglobulin heavy variable 2-70 Human genes 0.000 claims 1
- 102100040222 Immunoglobulin heavy variable 3-11 Human genes 0.000 claims 1
- 102100040221 Immunoglobulin heavy variable 3-13 Human genes 0.000 claims 1
- 102100040224 Immunoglobulin heavy variable 3-15 Human genes 0.000 claims 1
- 102100040218 Immunoglobulin heavy variable 3-20 Human genes 0.000 claims 1
- 102100040217 Immunoglobulin heavy variable 3-21 Human genes 0.000 claims 1
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 claims 1
- 102100040219 Immunoglobulin heavy variable 3-30 Human genes 0.000 claims 1
- 102100040236 Immunoglobulin heavy variable 3-33 Human genes 0.000 claims 1
- 102100028315 Immunoglobulin heavy variable 3-43 Human genes 0.000 claims 1
- 102100028320 Immunoglobulin heavy variable 3-48 Human genes 0.000 claims 1
- 102100028319 Immunoglobulin heavy variable 3-49 Human genes 0.000 claims 1
- 102100028317 Immunoglobulin heavy variable 3-53 Human genes 0.000 claims 1
- 102100028321 Immunoglobulin heavy variable 3-64 Human genes 0.000 claims 1
- 102100027821 Immunoglobulin heavy variable 3-66 Human genes 0.000 claims 1
- 102100040231 Immunoglobulin heavy variable 3-7 Human genes 0.000 claims 1
- 102100027820 Immunoglobulin heavy variable 3-72 Human genes 0.000 claims 1
- 102100027822 Immunoglobulin heavy variable 3-73 Human genes 0.000 claims 1
- 102100028305 Immunoglobulin heavy variable 3-74 Human genes 0.000 claims 1
- 102100040234 Immunoglobulin heavy variable 3-9 Human genes 0.000 claims 1
- 102100028311 Immunoglobulin heavy variable 4-28 Human genes 0.000 claims 1
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 claims 1
- 102100028306 Immunoglobulin heavy variable 4-34 Human genes 0.000 claims 1
- 102100028312 Immunoglobulin heavy variable 4-39 Human genes 0.000 claims 1
- 102100028308 Immunoglobulin heavy variable 4-4 Human genes 0.000 claims 1
- 102100028405 Immunoglobulin heavy variable 4-59 Human genes 0.000 claims 1
- 102100029419 Immunoglobulin heavy variable 4-61 Human genes 0.000 claims 1
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 claims 1
- 102100029416 Immunoglobulin heavy variable 6-1 Human genes 0.000 claims 1
- 102100020946 Immunoglobulin kappa variable 1-16 Human genes 0.000 claims 1
- 102100020945 Immunoglobulin kappa variable 1-17 Human genes 0.000 claims 1
- 102100020902 Immunoglobulin kappa variable 1-27 Human genes 0.000 claims 1
- 102100020901 Immunoglobulin kappa variable 1-33 Human genes 0.000 claims 1
- 102100020769 Immunoglobulin kappa variable 1-5 Human genes 0.000 claims 1
- 102100020768 Immunoglobulin kappa variable 1-6 Human genes 0.000 claims 1
- 102100020771 Immunoglobulin kappa variable 1-8 Human genes 0.000 claims 1
- 102100020770 Immunoglobulin kappa variable 1-9 Human genes 0.000 claims 1
- 102100027412 Immunoglobulin kappa variable 1D-12 Human genes 0.000 claims 1
- 102100027411 Immunoglobulin kappa variable 1D-13 Human genes 0.000 claims 1
- 102100027462 Immunoglobulin kappa variable 1D-16 Human genes 0.000 claims 1
- 102100027464 Immunoglobulin kappa variable 1D-33 Human genes 0.000 claims 1
- 102100027404 Immunoglobulin kappa variable 1D-39 Human genes 0.000 claims 1
- 102100030883 Immunoglobulin kappa variable 1D-43 Human genes 0.000 claims 1
- 102100027406 Immunoglobulin kappa variable 1D-8 Human genes 0.000 claims 1
- 102100022947 Immunoglobulin kappa variable 2-24 Human genes 0.000 claims 1
- 102100022950 Immunoglobulin kappa variable 2-28 Human genes 0.000 claims 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 1
- 102100022948 Immunoglobulin kappa variable 2-40 Human genes 0.000 claims 1
- 102100027460 Immunoglobulin kappa variable 2D-26 Human genes 0.000 claims 1
- 102100027459 Immunoglobulin kappa variable 2D-28 Human genes 0.000 claims 1
- 102100027458 Immunoglobulin kappa variable 2D-29 Human genes 0.000 claims 1
- 102100027409 Immunoglobulin kappa variable 2D-40 Human genes 0.000 claims 1
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 claims 1
- 102100022965 Immunoglobulin kappa variable 3-15 Human genes 0.000 claims 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 1
- 102100027405 Immunoglobulin kappa variable 3D-11 Human genes 0.000 claims 1
- 102100027410 Immunoglobulin kappa variable 3D-15 Human genes 0.000 claims 1
- 102100027403 Immunoglobulin kappa variable 3D-20 Human genes 0.000 claims 1
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 claims 1
- 102100038241 Immunoglobulin kappa variable 5-2 Human genes 0.000 claims 1
- 102100034806 Immunoglobulin kappa variable 6-21 Human genes 0.000 claims 1
- 102100027402 Immunoglobulin kappa variable 6D-21 Human genes 0.000 claims 1
- 102100026916 Immunoglobulin lambda variable 1-36 Human genes 0.000 claims 1
- 102100026911 Immunoglobulin lambda variable 1-40 Human genes 0.000 claims 1
- 102100026921 Immunoglobulin lambda variable 1-44 Human genes 0.000 claims 1
- 102100026809 Immunoglobulin lambda variable 1-47 Human genes 0.000 claims 1
- 102100026922 Immunoglobulin lambda variable 1-51 Human genes 0.000 claims 1
- 102100027972 Immunoglobulin lambda variable 10-54 Human genes 0.000 claims 1
- 102100038432 Immunoglobulin lambda variable 2-11 Human genes 0.000 claims 1
- 102100038429 Immunoglobulin lambda variable 2-14 Human genes 0.000 claims 1
- 102100038431 Immunoglobulin lambda variable 2-18 Human genes 0.000 claims 1
- 102100038430 Immunoglobulin lambda variable 2-23 Human genes 0.000 claims 1
- 102100038428 Immunoglobulin lambda variable 2-8 Human genes 0.000 claims 1
- 102100025921 Immunoglobulin lambda variable 3-1 Human genes 0.000 claims 1
- 102100025919 Immunoglobulin lambda variable 3-10 Human genes 0.000 claims 1
- 102100025920 Immunoglobulin lambda variable 3-12 Human genes 0.000 claims 1
- 102100025936 Immunoglobulin lambda variable 3-16 Human genes 0.000 claims 1
- 102100025937 Immunoglobulin lambda variable 3-19 Human genes 0.000 claims 1
- 102100025934 Immunoglobulin lambda variable 3-21 Human genes 0.000 claims 1
- 102100025935 Immunoglobulin lambda variable 3-22 Human genes 0.000 claims 1
- 102100025876 Immunoglobulin lambda variable 3-25 Human genes 0.000 claims 1
- 102100025874 Immunoglobulin lambda variable 3-27 Human genes 0.000 claims 1
- 102100025864 Immunoglobulin lambda variable 3-9 Human genes 0.000 claims 1
- 102100025865 Immunoglobulin lambda variable 4-3 Human genes 0.000 claims 1
- 102100025862 Immunoglobulin lambda variable 4-60 Human genes 0.000 claims 1
- 102100025863 Immunoglobulin lambda variable 4-69 Human genes 0.000 claims 1
- 102100025856 Immunoglobulin lambda variable 5-37 Human genes 0.000 claims 1
- 102100025857 Immunoglobulin lambda variable 5-39 Human genes 0.000 claims 1
- 102100025855 Immunoglobulin lambda variable 5-45 Human genes 0.000 claims 1
- 102100023753 Immunoglobulin lambda variable 5-52 Human genes 0.000 claims 1
- 102100023747 Immunoglobulin lambda variable 6-57 Human genes 0.000 claims 1
- 102100023746 Immunoglobulin lambda variable 7-43 Human genes 0.000 claims 1
- 102100023751 Immunoglobulin lambda variable 7-46 Human genes 0.000 claims 1
- 102100023754 Immunoglobulin lambda variable 9-49 Human genes 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 229940124761 MMP inhibitor Drugs 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000014736 Notch Human genes 0.000 claims 1
- 108010070047 Notch Receptors Proteins 0.000 claims 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims 1
- 102400000979 Pituitary adenylate cyclase-activating polypeptide 38 Human genes 0.000 claims 1
- 102100035194 Placenta growth factor Human genes 0.000 claims 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 102100040223 Probable non-functional immunoglobulin heavy variable 3-16 Human genes 0.000 claims 1
- 102100040226 Probable non-functional immunoglobulin heavy variable 3-35 Human genes 0.000 claims 1
- 102100028318 Probable non-functional immunoglobulin heavy variable 3-38 Human genes 0.000 claims 1
- 102100029413 Probable non-functional immunoglobulin heavy variable 7-81 Human genes 0.000 claims 1
- 102100030884 Probable non-functional immunoglobulin kappa variable 1D-42 Human genes 0.000 claims 1
- 102100027461 Probable non-functional immunoglobulin kappa variable 2D-24 Human genes 0.000 claims 1
- 102100022959 Probable non-functional immunoglobulin kappa variable 3-7 Human genes 0.000 claims 1
- 102100030885 Probable non-functional immunoglobulin kappa variable 6D-41 Human genes 0.000 claims 1
- 102100026912 Probable non-functional immunoglobulin lambda variable 1-50 Human genes 0.000 claims 1
- 102100023451 Probable non-functional immunoglobulin lambda variable 11-55 Human genes 0.000 claims 1
- 102100038489 Probable non-functional immunoglobulin lambda variable 2-33 Human genes 0.000 claims 1
- 102100025868 Probable non-functional immunoglobulin lambda variable 3-32 Human genes 0.000 claims 1
- 102100020904 Probable non-functional immunoglobulinn kappa variable 1-37 Human genes 0.000 claims 1
- 102100027463 Probable non-functional immunoglobulinn kappa variable 1D-37 Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 101710113649 Thyroid peroxidase Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 230000008611 intercellular interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010082117 matrigel Proteins 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19876408P | 2008-11-07 | 2008-11-07 | |
| US61/198,764 | 2008-11-07 | ||
| US21120409P | 2009-03-25 | 2009-03-25 | |
| US61/211,204 | 2009-03-25 | ||
| PCT/US2009/063299 WO2010054007A1 (en) | 2008-11-07 | 2009-11-04 | Combinatorial antibody libraries and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016018531A Division JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508016A JP2012508016A (ja) | 2012-04-05 |
| JP2012508016A5 true JP2012508016A5 (enExample) | 2013-01-24 |
| JP5882058B2 JP5882058B2 (ja) | 2016-03-09 |
Family
ID=41508157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535649A Expired - Fee Related JP5882058B2 (ja) | 2008-11-07 | 2009-11-04 | 組合せ抗体ライブラリー及びその使用 |
| JP2011535651A Pending JP2012508017A (ja) | 2008-11-07 | 2009-11-04 | 抗ｄｌｌ４抗体及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535651A Pending JP2012508017A (ja) | 2008-11-07 | 2009-11-04 | 抗ｄｌｌ４抗体及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9221902B2 (enExample) |
| EP (2) | EP2356270B1 (enExample) |
| JP (4) | JP5882058B2 (enExample) |
| AU (4) | AU2009313560B2 (enExample) |
| CA (2) | CA2742968C (enExample) |
| DK (1) | DK2356270T3 (enExample) |
| WO (2) | WO2010054010A1 (enExample) |
Families Citing this family (203)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| HUE028379T2 (en) | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| US8420779B2 (en) | 2007-05-22 | 2013-04-16 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| KR20100126811A (ko) | 2008-03-14 | 2010-12-02 | 바이오콘 리미티드 | 모노클로날 항체 및 그것의 방법 |
| JP5882058B2 (ja) | 2008-11-07 | 2016-03-09 | ファブラス エルエルシー | 組合せ抗体ライブラリー及びその使用 |
| EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| WO2010121370A1 (en) * | 2009-04-20 | 2010-10-28 | University Health Network | Prognostic gene expression signature for squamous cell carcinoma of the lung |
| ES2511051T3 (es) | 2009-05-29 | 2014-10-22 | Morphosys Ag | Colección de anticuerpos sintéticos para tratar enfermedades |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| TR201818814T4 (tr) | 2009-10-16 | 2019-01-21 | Oncomed Pharm Inc | Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı. |
| EP2496600A1 (en) | 2009-11-04 | 2012-09-12 | Fabrus LLC | Methods for affinity maturation-based antibody optimization |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| US10016620B2 (en) * | 2010-02-04 | 2018-07-10 | Procept Biorobotics Incorporation | Tissue sampling and cancer treatment apparatus |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| NZ631363A (en) | 2010-02-08 | 2016-05-27 | Regeneron Pharma | Common light chain mouse |
| US9354228B2 (en) | 2010-07-16 | 2016-05-31 | Adimab, Llc | Antibody libraries |
| CA2806076A1 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| KR20130110169A (ko) | 2010-09-22 | 2013-10-08 | 암젠 인크 | 담체 면역글로뷸린 및 이것의 용도 |
| SG189950A1 (en) | 2010-11-19 | 2013-06-28 | Morphosys Ag | A collection and methods for its use |
| US20160272697A2 (en) * | 2011-04-28 | 2016-09-22 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Neutralizing Antibodies to Nipah and Hendra Virus |
| CA3078215A1 (en) * | 2011-04-28 | 2012-11-01 | Department Of Veterans Affairs | Identification of polynucleotides associated with a sample |
| CA3025762C (en) * | 2011-05-04 | 2021-11-09 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| CN103596984B (zh) * | 2011-06-15 | 2016-04-13 | 霍夫曼-拉罗奇有限公司 | 抗-人epo受体的抗体及使用方法 |
| DK2739740T3 (da) | 2011-08-05 | 2019-12-09 | Regeneron Pharma | Universelle, humaniserede letkæde-mus |
| DK2744931T3 (en) * | 2011-08-18 | 2018-08-06 | Affinity Biosciences Pty Ltd | SOLUBLE POLYPEPTIDES |
| ES2707580T3 (es) | 2011-09-23 | 2019-04-04 | Oncomed Pharm Inc | Agentes de unión a VEGF/DLL4 y usos de los mismos |
| WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| EP2773665A1 (en) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
| AU2013208003B2 (en) | 2012-01-09 | 2017-12-14 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| EP2802601B1 (en) | 2012-01-09 | 2019-11-13 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| US9150648B2 (en) * | 2012-01-31 | 2015-10-06 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| WO2013131074A1 (en) * | 2012-03-02 | 2013-09-06 | Diogenix, Inc. | Methods and reagents for evaluating autoimmune disease and determining antibody repertoire |
| WO2013134743A1 (en) | 2012-03-08 | 2013-09-12 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| CA2875543A1 (en) * | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
| US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| WO2014071018A1 (en) * | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| WO2014074528A2 (en) * | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
| WO2014085821A2 (en) * | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-met |
| LT2928921T (lt) | 2012-12-05 | 2021-04-26 | Novartis Ag | Kompozicijos ir būdai, skirti antikūnams nukreipti į epo |
| WO2014116051A1 (ko) | 2013-01-24 | 2014-07-31 | 스크립스코리아 항체연구원 | 단백질 조합 기반의 Fv 라이브러리 및 이의 제조 방법 |
| US9896685B2 (en) | 2013-04-25 | 2018-02-20 | Sutro Biopharma, Inc. | Use of LAMBDA-GAM protein in ribosomal display technology |
| US20160069897A1 (en) * | 2013-04-25 | 2016-03-10 | Suthro Biopharma, Inc. | Selection of fab fragments using ribosomal display technology |
| RU2539752C2 (ru) * | 2013-05-23 | 2015-01-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
| CA2918370A1 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
| PL3052192T3 (pl) * | 2013-10-02 | 2021-04-06 | Medimmune, Llc | Przeciwciała neutralizujące przeciwko grypie A i ich zastosowania |
| WO2015057906A1 (en) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| ES2897765T3 (es) * | 2014-03-14 | 2022-03-02 | Hoffmann La Roche | Procedimientos y composiciones para la secreción de polipéptidos heterólogos |
| KR102601491B1 (ko) | 2014-03-21 | 2023-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| CN106459213B (zh) | 2014-04-03 | 2020-12-01 | Igm生物科学股份有限公司 | 修饰的j链 |
| EP3126397B1 (en) | 2014-04-04 | 2020-01-29 | Bionomics, Inc. | Humanized antibodies that bind lgr5 |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| EP3160566B1 (en) * | 2014-06-24 | 2020-03-11 | Procept Biorobotics Corporation | Tissue sampling and cancer treatment apparatus |
| CN113563462B (zh) | 2014-07-15 | 2024-08-13 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| EP3185897A4 (en) * | 2014-08-29 | 2018-05-02 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind oprf and opri |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| JP6709215B2 (ja) | 2014-10-27 | 2020-06-10 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 抗ｔｉｍ−３抗体 |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| TW201625692A (zh) | 2014-11-14 | 2016-07-16 | 諾華公司 | 抗體藥物結合物 |
| EP3026060A1 (en) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
| SG11201704549UA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| CN113388036A (zh) | 2014-12-05 | 2021-09-14 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的抗体及其用途 |
| EP3246434A1 (en) * | 2015-01-13 | 2017-11-22 | Ewha University-Industry Collaboration Foundation | Method for preparing novel antibody library and library prepared thereby |
| MX2017011600A (es) | 2015-03-10 | 2018-06-13 | Sorrento Therapeutics Inc | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| EP3280443B1 (en) | 2015-04-08 | 2022-08-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| AR104309A1 (es) | 2015-04-17 | 2017-07-12 | Bayer Pharma AG | Construcciones de anticuerpos biespecíficos para cdh3 y cd3 |
| KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
| US10787517B2 (en) | 2015-05-18 | 2020-09-29 | Agensys, Inc. | Antibodies that bind to AXL proteins |
| EP3297662A4 (en) | 2015-05-18 | 2019-03-13 | Agensys, Inc. | ANTIBODIES BINDING TO AXL PROTEINS |
| LT3303384T (lt) | 2015-06-01 | 2021-10-11 | Medimmune, Llc | Neutralizuojančios surišančios molekulės prieš gripą ir jų naudojimas |
| US20180155411A1 (en) * | 2015-07-08 | 2018-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Heterotypic antibodies specific for human rotavirus |
| CN107922975B (zh) | 2015-08-12 | 2022-06-28 | 诺华股份有限公司 | 治疗眼科病症的方法 |
| JP6967003B2 (ja) | 2015-09-23 | 2021-11-17 | メレオ バイオファーマ ５ インコーポレイテッド | がんの処置のための方法および組成物 |
| DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| EP3824903A1 (en) | 2015-09-30 | 2021-05-26 | IGM Biosciences Inc. | Binding molecules with modified j-chain |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| HUE050312T2 (hu) | 2015-11-10 | 2020-11-30 | Medimmune Llc | ASCT2-RE specifikus kötõmolekulák és alkalmazásaik |
| EP3383914A4 (en) * | 2015-12-02 | 2019-10-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF |
| CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2017096182A1 (en) * | 2015-12-03 | 2017-06-08 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| CN105693821A (zh) * | 2016-01-08 | 2016-06-22 | 中国药科大学 | 与人血管内皮生长因子受体-3(vegfr-3)蛋白特异性结合的多肽，其筛选方法，鉴定和用途 |
| US11136407B2 (en) * | 2016-01-08 | 2021-10-05 | Aimm Therapeutics B.V. | Therapeutic anti-CD9 antibody |
| IL304940A (en) | 2016-01-13 | 2023-10-01 | Medimmune Llc | A method for treating type A influenza |
| JP7022067B2 (ja) * | 2016-01-14 | 2022-02-17 | メモリアル スローン ケタリング キャンサー センター | Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体 |
| KR20180138205A (ko) | 2016-03-22 | 2018-12-28 | 바이오노믹스 리미티드 | 항-lgr5 단클론성 항체의 투여 |
| US11197937B2 (en) * | 2016-04-15 | 2021-12-14 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| MX2018015757A (es) * | 2016-06-14 | 2019-05-30 | Merck Sharp & Dohme | Anticuerpos antifactor de la coagulacion xi. |
| IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Anti-pd-l1 antibodies |
| JP6987134B2 (ja) | 2016-06-27 | 2021-12-22 | ジュノー セラピューティクス インコーポレイテッド | ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途 |
| MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| EP3510046A4 (en) * | 2016-09-07 | 2020-05-06 | The Regents of the University of California | ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES |
| CN118005799A (zh) * | 2016-09-23 | 2024-05-10 | 马伦戈治疗公司 | 包含λ轻链和κ轻链的多特异性抗体分子 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US11667697B2 (en) | 2016-10-19 | 2023-06-06 | Vanderbilt University | Human orthopoxvirus antibodies and methods of use therefor |
| WO2018081754A1 (en) * | 2016-10-29 | 2018-05-03 | University Of Miami | Anti-zika virus antibodies |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| ES3040144T3 (en) | 2016-11-08 | 2025-10-28 | Regeneron Pharma | Antigen-binding proteins that antagonize leptin receptor |
| WO2018089628A1 (en) * | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| TW201832778A (zh) * | 2016-11-10 | 2018-09-16 | 美商麥迪紐有限責任公司 | 對ａｓｃｔ２具有特異性的結合分子及其用途 |
| BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharmaceuticals, Inc. | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
| SI3555132T1 (sl) * | 2016-12-19 | 2024-04-30 | Medimmune Limited | Protitelesa proti LIF in njihove uporabe |
| KR20190118172A (ko) | 2017-02-08 | 2019-10-17 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CA3052779A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CN110637031B (zh) * | 2017-03-04 | 2024-04-16 | 湘潭腾华生物科技有限公司 | 程序性死亡蛋白1(pd-1)的重组抗体及其用途 |
| JOP20180021A1 (ar) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US10296425B2 (en) | 2017-04-20 | 2019-05-21 | Bank Of America Corporation | Optimizing data processing across server clusters and data centers using checkpoint-based data replication |
| US11976121B2 (en) | 2017-07-20 | 2024-05-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CD123-binding chimeric antigen receptors |
| IL316357A (en) * | 2017-07-31 | 2024-12-01 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| CA3072816A1 (en) * | 2017-08-18 | 2019-02-21 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared antigens |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| DK3703750T3 (da) | 2017-11-01 | 2025-02-10 | Juno Therapeutics Inc | Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider |
| KR20200099137A (ko) | 2017-11-06 | 2020-08-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법 및 감마 세크레타제 억제제의 조합 |
| JP7291700B2 (ja) | 2017-11-20 | 2023-06-15 | ナントバイオ，インコーポレイテッド | ｍＲＮＡディスプレイ抗体ライブラリー及び方法 |
| US11034951B2 (en) | 2017-11-20 | 2021-06-15 | Nantbio, Inc. | mRNA display antibody library and methods |
| KR20200100089A (ko) | 2017-12-18 | 2020-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법 |
| AU2018393074B2 (en) | 2017-12-19 | 2025-10-23 | Surrozen Operating, Inc. | Anti-frizzled antibodies and methods of use |
| US11746150B2 (en) | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| CN111727203B (zh) | 2017-12-19 | 2024-04-26 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| WO2019143884A1 (en) * | 2018-01-19 | 2019-07-25 | Vanderbilt University | Conserved hiv antibody clonotypes and methods of use |
| WO2019157366A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| MX2020008684A (es) * | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| AU2019232631A1 (en) | 2018-03-05 | 2020-09-24 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| TW201940515A (zh) * | 2018-03-13 | 2019-10-16 | 英商塔斯克療法有限公司 | 抗-cd25抗體藥劑 |
| WO2019195796A1 (en) | 2018-04-06 | 2019-10-10 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
| EP3553082A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| EP3553079A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| WO2020010235A1 (en) * | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
| WO2020014143A1 (en) | 2018-07-08 | 2020-01-16 | Specifica Inc. | Antibody libraries with maximized antibody developability characteristics |
| CN110713537B (zh) * | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | 一种sema4d抗体及其制备方法和应用 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EP3844266A1 (en) | 2018-08-28 | 2021-07-07 | Fred Hutchinson Cancer Research Center | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| CN109553680B (zh) * | 2018-12-12 | 2021-06-01 | 广州市第八人民医院 | 一种单克隆抗体ZKns4B8及其应用 |
| BR112021012569A2 (pt) * | 2018-12-28 | 2021-09-14 | Kyowa Kirin Co., Ltd. | Anticorpo biespecífico de ligação ao tfr |
| JP7550770B2 (ja) * | 2019-01-31 | 2024-09-13 | ナントバイオ，インコーポレイテッド | ｍＲＮＡディスプレイ抗体ライブラリー及び方法 |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US12479908B2 (en) | 2019-03-29 | 2025-11-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Antibodies against programmed cell death protein 1 (PD1) and uses thereof |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| GB2600274B (en) | 2019-06-07 | 2024-11-27 | Scribe Therapeutics Inc | Engineered CasX systems |
| WO2020247883A2 (en) * | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| US12448462B2 (en) | 2019-06-14 | 2025-10-21 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 |
| AU2020300618A1 (en) * | 2019-07-02 | 2022-01-27 | Surrozen Operating, Inc. | Monospecific anti-frizzled antibodies and methods of use |
| EP3999532A2 (en) * | 2019-07-16 | 2022-05-25 | Sanofi | Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease |
| CN115003697A (zh) | 2019-09-23 | 2022-09-02 | 特韦斯特生物科学公司 | Crth2的变异核酸文库 |
| US12173282B2 (en) * | 2019-09-23 | 2024-12-24 | Twist Bioscience, Inc. | Antibodies that bind CD3 epsilon |
| BR112022007720A2 (pt) * | 2019-10-24 | 2022-08-23 | Prometheus Biosciences Inc | Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos |
| WO2021202863A1 (en) * | 2020-04-02 | 2021-10-07 | Promab Biotechnologies, Inc. | Human ror-1 antibody and anti-ror-1-car-t cells |
| JP2023523336A (ja) * | 2020-04-27 | 2023-06-02 | ツイスト バイオサイエンス コーポレーション | コロナウイルス用の変異体核酸ライブラリー |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| AU2021277373A1 (en) * | 2020-05-20 | 2023-01-05 | The Trustees Of Columbia University In The City Of New York | Potent neutralizing antibodies against SARS-CoV-2, generation and uses thereof |
| CN111748033B (zh) * | 2020-05-27 | 2021-02-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
| IL298510A (en) | 2020-06-12 | 2023-01-01 | Nkarta Inc | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| TWI806088B (zh) * | 2020-06-30 | 2023-06-21 | 大陸商和鉑醫藥（上海）有限責任公司 | 具有H2L2與HCAb結構的結合蛋白 |
| AU2021324615A1 (en) * | 2020-08-10 | 2023-03-09 | Integral Molecular, Inc. | Methods and compositions for making antibody libraries and antibodies isolated from the same |
| US20230391856A1 (en) * | 2020-10-23 | 2023-12-07 | Icahn School Of Medicine At Mount Sinai | Sars-cov-2 antibodies and uses thereof |
| EP4256054A1 (en) | 2020-12-03 | 2023-10-11 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| JP2023552762A (ja) * | 2020-12-04 | 2023-12-19 | エクイリウム，インコーポレイテッド | Ｃｄ６ｈｉｇｈ細胞を選択的に標的化してｔｅｆｆ細胞の活性を低下する方法 |
| CN117203228A (zh) * | 2021-01-11 | 2023-12-08 | 阿迪马布有限责任公司 | 被工程化为优先进行链配对的变体ch1结构域和变体cl结构域以及包括所述变体ch1结构域和所述变体cl结构域的多特异性抗体 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20240327503A1 (en) * | 2021-03-12 | 2024-10-03 | Jimmy Dale GOLLIHAR | Sars-cov-2 neutralizing antibodies and uses thereof |
| WO2022204316A2 (en) | 2021-03-24 | 2022-09-29 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
| WO2022266383A1 (en) * | 2021-06-17 | 2022-12-22 | Atreca, Inc. | Anti-csp antibodies |
| JP2024526324A (ja) * | 2021-07-12 | 2024-07-17 | ンカルタ・インコーポレイテッド | Ｂｃｍａ指向性細胞免疫療法の組成物および方法 |
| CA3227150A1 (en) * | 2021-07-23 | 2023-01-26 | The Trustees Of Columbia University In The City Of New York | Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use |
| JP2024527029A (ja) | 2021-07-29 | 2024-07-19 | セファロン リミティド ライアビリティ カンパニー | 抗ｐａｃａｐ抗体の組成物及び方法 |
| US11987641B2 (en) | 2021-08-27 | 2024-05-21 | Janssen Biotech, Inc. | Anti-PSMA antibodies and uses thereof |
| AU2022335002A1 (en) * | 2021-08-27 | 2024-04-11 | Janssen Biotech, Inc. | Anti-psma radioconjugates and uses thereof |
| CN118234750A (zh) * | 2021-09-02 | 2024-06-21 | 纪念斯隆-凯特琳癌症中心 | 抗cd33抗体和其用途 |
| AU2022340644A1 (en) * | 2021-09-02 | 2024-02-29 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting cd33 and uses thereof |
| WO2023034950A2 (en) * | 2021-09-03 | 2023-03-09 | Icahn School Of Medicine At Mount Sinai | Anti-hcmv antibodies and antigen-binding fragments thereof |
| EP4466284A2 (en) * | 2021-10-27 | 2024-11-27 | Twist Bioscience Corporation | Multispecific sars-cov-2 antibodies and methods of use |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
| EP4486382A2 (en) * | 2022-03-04 | 2025-01-08 | Coagulant Therapeutics Corporation | Human antibodies against activated protein c and uses thereof |
| JP2025534161A (ja) * | 2022-10-04 | 2025-10-14 | ミンク セラピューティクス， インコーポレイテッド | 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用 |
| AU2024240129A1 (en) | 2023-03-17 | 2025-10-09 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| CN116514998B (zh) * | 2023-05-12 | 2023-09-15 | 再少年(北京)生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用 |
| WO2025010375A2 (en) * | 2023-07-03 | 2025-01-09 | Uct Bioscience Co., Ltd. | Anti-grp78 antibodies and their uses |
| WO2025015320A2 (en) * | 2023-07-12 | 2025-01-16 | Phenomic Ai | Anti-cthrc1 t cell engagers and methods of using the same |
| TW202525855A (zh) * | 2023-08-31 | 2025-07-01 | 美商艾克塞里克斯公司 | Ｉｌｔ２結合劑及其用途 |
| TW202515919A (zh) * | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| WO2025081163A1 (en) * | 2023-10-13 | 2025-04-17 | GenCART, Inc. | Compositions for the treatment of cancer |
| US20250255980A1 (en) * | 2024-02-12 | 2025-08-14 | Mbrace Therapeutics, Inc. | Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) |
| WO2025184137A1 (en) * | 2024-02-27 | 2025-09-04 | Adimab, Llc | Influenza antibodies and methods of use thereof |
| CN117986346B (zh) * | 2024-04-07 | 2024-07-26 | 中国人民解放军军事科学院军事医学研究院 | 一种tpo模拟肽及其应用 |
| CN120399078A (zh) * | 2025-05-08 | 2025-08-01 | 上海天泽云泰生物医药有限公司 | 靶向cd117的纳米抗体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| JP3127158B2 (ja) | 1989-10-05 | 2001-01-22 | オプテイン，インコーポレイティド | 新規の遺伝子及びポリペチドの無細胞合成並びに単離 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US20030036092A1 (en) | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| AU6952498A (en) | 1997-04-04 | 1998-10-30 | Millenium Pharmaceuticals, Inc. | Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
| DK1004669T3 (da) | 1997-05-14 | 2007-08-27 | Asahi Chemical Ind | Hidtil ukendte differentieringsinhibitor |
| CA2337492A1 (en) | 1998-07-27 | 2000-02-10 | Amgen Inc. | Delta-related polypeptides |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US20020102613A1 (en) | 1999-05-18 | 2002-08-01 | Hoogenboom Hendricus Renerus Jacobus Mattheus | Novel Fab fragment libraries and methods for their use |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| WO2001097850A2 (en) | 2000-06-23 | 2001-12-27 | Schering Aktiengesellschaft | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
| US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
| EP1438402A2 (en) | 2001-08-22 | 2004-07-21 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
| WO2003035842A2 (en) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
| CA2485732A1 (en) * | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20120202710A1 (en) * | 2003-09-09 | 2012-08-09 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| EP1848672A4 (en) | 2005-02-01 | 2009-11-04 | Morphosys Ag | LIBRARIES AND METHOD FOR ISOLATING ANTIBODIES |
| US8716195B2 (en) | 2005-11-14 | 2014-05-06 | Bioren, Inc. | Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening |
| CA2630839C (en) | 2005-12-16 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
| WO2007137616A1 (en) | 2006-05-30 | 2007-12-06 | Millegen | Highly diversified antibody libraries |
| CL2007001623A1 (es) | 2006-06-06 | 2008-01-18 | Genentech Inc | Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo. |
| JP2009539870A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 血管発生の調節ための組成物および方法 |
| CN101500605B (zh) | 2006-08-07 | 2014-04-30 | 瑞泽恩制药公司 | Dll4拮抗剂在治疗局部缺血性损伤中的用途 |
| HUE028379T2 (en) * | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| US20080100597A1 (en) | 2006-10-25 | 2008-05-01 | Macrovision Corporation | Method and apparatus to improve playability in overscan areas of a TV display |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| JP2010517944A (ja) | 2007-01-26 | 2010-05-27 | バイオインヴェント インターナショナル アーベー | Ｄｌｌ４シグナリング阻害薬およびその使用 |
| GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| JP5882058B2 (ja) | 2008-11-07 | 2016-03-09 | ファブラス エルエルシー | 組合せ抗体ライブラリー及びその使用 |
-
2009
- 2009-11-04 JP JP2011535649A patent/JP5882058B2/ja not_active Expired - Fee Related
- 2009-11-04 JP JP2011535651A patent/JP2012508017A/ja active Pending
- 2009-11-04 WO PCT/US2009/063303 patent/WO2010054010A1/en not_active Ceased
- 2009-11-04 CA CA2742968A patent/CA2742968C/en not_active Expired - Fee Related
- 2009-11-04 AU AU2009313560A patent/AU2009313560B2/en not_active Ceased
- 2009-11-04 US US13/128,219 patent/US9221902B2/en active Active
- 2009-11-04 DK DK09748671.6T patent/DK2356270T3/da active
- 2009-11-04 AU AU2009313551A patent/AU2009313551B2/en not_active Ceased
- 2009-11-04 WO PCT/US2009/063299 patent/WO2010054007A1/en not_active Ceased
- 2009-11-04 US US13/128,236 patent/US9403904B2/en not_active Expired - Fee Related
- 2009-11-04 EP EP09748671.6A patent/EP2356270B1/en active Active
- 2009-11-04 EP EP09748672A patent/EP2356146A1/en not_active Withdrawn
- 2009-11-04 CA CA2742969A patent/CA2742969A1/en not_active Abandoned
-
2015
- 2015-08-10 JP JP2015157842A patent/JP2016040246A/ja active Pending
- 2015-12-04 US US14/959,940 patent/US10774138B2/en active Active
-
2016
- 2016-02-03 JP JP2016018531A patent/JP2016127850A/ja active Pending
- 2016-07-07 AU AU2016204719A patent/AU2016204719A1/en not_active Abandoned
-
2018
- 2018-03-06 AU AU2018201622A patent/AU2018201622A1/en not_active Abandoned
-
2020
- 2020-08-25 US US17/002,749 patent/US20200399359A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508016A5 (enExample) | ||
| Shen et al. | Single variable domain-IgG fusion: a novel recombinant approach to Fc domain-containing bispecific antibodies | |
| JP2020536504A5 (enExample) | ||
| JP7668617B2 (ja) | ｐＨ依存的抗体の調製方法 | |
| Ylera et al. | Off-rate screening for selection of high-affinity anti-drug antibodies | |
| DK2606064T3 (en) | Methods for generating multispecific and multivalent antibodies | |
| JP6437913B2 (ja) | 複合体特異的抗体及び抗体断片並びにその使用 | |
| Peng et al. | Mining naive rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility | |
| CN1345334A (zh) | 对kdr特异的抗体及其应用 | |
| CA2896548A1 (en) | Multivalent binding protein compositions | |
| JPWO2019137548A5 (enExample) | ||
| CA2780221A1 (en) | Methods for affinity maturation-based antibody optimization | |
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| CN116444667B (zh) | 一种靶向gdf15的全人源抗体及其应用 | |
| AU2018367622B2 (en) | mRNA display antibody library and methods | |
| Hust et al. | Antibody phage display | |
| Keller et al. | Selection of scFv antibody fragments binding to human blood versus lymphatic endothelial surface antigens by direct cell phage display | |
| WO2022157773A2 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| JP2021503292A5 (enExample) | ||
| JPWO2019175368A5 (enExample) | ||
| WO2021084104A1 (en) | Tetravalent antibody molecules | |
| US20200141930A1 (en) | Method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto | |
| CN114891108B (zh) | 一种靶向bcma的全人源抗体及其应用 | |
| CN115991776B (zh) | 一种靶向cd7的全人源抗体及其应用 | |
| CN113784988B (zh) | 特异性结合ccsp-2的单克隆抗体及其用途 |